Global languages
2023-05-04
Regulatory

Sales affected by temporary inventory reductions and COVID in APAC

Organic sales growth:
Q1, 2023: -21% (15)

EBITDA margin:
Q1, 2023: 25% (36)

Summary, January 1-March 31, 2023

  • Net sales decreased by 14% to SEK 139 m (162).
  • Sales decreased organically by 21% (+15), currency effect 7%.
  • EBITDA amounted to SEK 35 m (59).
  • EBITDA margin amounted to 25% (36).
  • Profit before tax amounted to SEK 24 m (49).
  • Earnings per share before and after dilution amounted to SEK 0.81 (1.61).
  • Cash flow from operating activities amounted to SEK 19 m (38).

Contact

Adele Horn
Corporate Communications & Investor Relations
Direct: + 46 46 460 26 04
Mobile: + 46 72 206 50 88
www.cellavision.com
adele.horn@cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 16 local market support organizations covering more than 40 countries. In 2022, sales were SEK 639 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-04 07:20 CEST.

Attachments

Interim Report Q1 2023

Share